The Use of PET in Radiation Therapy for Lymphoma

John P Plastaras; Geoffrey Geiger; Rodolfo Perini; Eli Glatstein

doi:10.1016/j.cpet.2011.12.005

The Use of PET in Radiation Therapy for Lymphoma

PET Clin. 2012 Jan;7(1):67-72. doi: 10.1016/j.cpet.2011.12.005.

Authors

John P Plastaras¹, Geoffrey Geiger¹, Rodolfo Perini², Eli Glatstein¹

Affiliations

¹ Department of Radiation Oncology, Perelman Center for Advanced Medicine, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
² Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Pennsylvania, 3400 Spruce Street, Donner 110-B, Philadelphia, PA 19104, USA; Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, 3400 Spruce Street, Donner 110-B, Philadelphia, PA 19104, USA.

PMID: 27157019
DOI: 10.1016/j.cpet.2011.12.005

Abstract

Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) and computed tomography (CT) has essentially replaced CT alone for staging of lymphomas. FDG-PET has been incorporated into the revised response criteria, but response adapted strategies are still being evaluated. The role of FDG-PET/CT in radiation treatment planning is still being developed. It is unclear how to use FDG-PET/CT to determine whether to give consolidative radiation, where to radiate, and what dose. Ongoing efforts are underway to use early interim FDG-PET/CT to limit therapy in good prognosis patients. A multidisciplinary team is important in the management of patients with lymphoma, leading to individualized treatment plans and better outcomes.